ELPI
ELPI Brand names, ELPI Analogs
- Abitrate
- Amotril
- Amotril S
- Angiokapsul
- Anparton
- Antilipid
- Antilipide
- Apolan
- Arterioflexin
- Arterosol
- Artes
- Artevil
- Ateculon
- Ateriosan
- Athebrate
- Atheromide
- Atheropront
- Athranid-Wirkstoff
- Atrolen
- Atromid
- Atromid S
- Atromid-S
- Atromida
- Atromidin
- Atrovis
- Azionyl
- Bioscleran
- Bresit
- CPIB
- Cartagyl
- Chlorfenisate
- Chlorophenoxyisobutyricacidethylester
- Chlorphenisate
- Cinnarizin
- Cinnarizine
- Citiflus
- Claripex
- Claripex CPIB
- Cloberat
- Clobrat
- Clobren-5F
- Clobren-SF
- Clofar
- Clofibate
- Clofibram
- Clofibrat
- Clofibrato
- Clofibratum
- Clofinit
- Clofipront
- Delipid
- Deliva
- Dura clofibrat
- ELPI
- EPIB
- Ethyl chlorophenoxyisobutyrate
- Ethyl clofibrate
- Ethyl p-chlorophenoxyisobutyrate
- Ethyl para-chlorophenoxyisobutyrate
- Fibralem
- Gerastop
- Hyclorate
- Klofibrat
- Klofiran
- Levatrom
- Lipamid
- Lipavil
- Lipavlon
- Lipide 500
- Lipidsenker
- Lipofacton
- Lipomid
- Liponorm
- Liporeduct
- Liporil
- Liposid
- Liprin
- Liprinal
- Lobetrin
- Miscleron
- Negalip
- Neo-Atromid
- Normalip
- Normat
- Normet
- Normolipol
- Novofibrate
- Oxan 600
- Persantinat
- Recolip
- Regardin
- Regelan
- Regelan N
- Robigram
- Scrobin
- Serofinex
- Serotinex
- Skerolip
- Sklerepmexe
- Sklero
- Sklero-Tablinen
- Sklero-tablinene
- Sklero-tabuls
- Sklerolip
- Skleromex
- Skleromexe
- Tetrasipton
- Thillate
- Thiosan
- Ticlobran
- Vincamin compositum
- Xyduril
- Yoclo
- neo-Atomid
ELPI Brand Names Mixture
- No information avaliable
ELPI Chemical_Formula
C12H15ClO3
ELPI RX_link
http://www.rxlist.com/cgi/generic2/clofibrate.htm
ELPI fda sheet
ELPI msds (material safety sheet)
ELPI Synthesis Reference
No information avaliable
ELPI Molecular Weight
242.698 g/mol
ELPI Melting Point
< 25 oC (boiling point 148-150°C at 25 mm Hg)
ELPI H2O Solubility
Insoluble
ELPI State
Liquid
ELPI LogP
3.58
ELPI Dosage Forms
Capsules (orange, oblong, soft-gelatin capsules, each containing 500 mg clofibrate)
ELPI Indication
For Primary Dysbetalipoproteinemia (Type III hyperlipidemia) that does not respond adequately to diet.
ELPI Pharmacology
Clofibrate is an antilipidemic agent similar to gemfibrozil. It acts to lower elevated serum lipids by reducing the very low-density lipoprotein fraction (Sf 20-400) rich in triglycerides. Serum cholesterol may be decreased, particularly in those patients whose cholesterol elevation is due to the presence of IDL as a result of Type III hyperlipoproteinemia. Several investigators have observed in their studies that clofibrate may produce a decrease in cholesterol linoleate but an increase in palmitoleate and oleate, the latter being considered atherogenic in experimental animals. The significance of this finding is unknown at this time. Reduction of triglycerides in some patients treated with clofibrate or certain of its chemically and clinically similar analogs may be associated with an increase in LDL cholesterol. Increase in LDL cholesterol has been observed in patients whose cholesterol is initially normal. Animal studies suggest that clofibrate interrupts cholesterol biosynthesis prior to mevalonate formation.
ELPI Absorption
Completely but slowly absorbed from the intestine. Between 95% and 99% of an oral dose of clofibrate is excreted in the urine as free and conjugated clofibric acid; thus, the absorption of clofibrate is virtually complete.
ELPI side effects and Toxicity
Oral, mouse: LD50 = 1220 mg/kg; Oral, rabbit: LD50 = 1370 mg/kg; Oral, rat: LD50 = 940 mg/kg. No reported case of overdosage in humans.
ELPI Patient Information
ELPI Organisms Affected
Humans and other mammals
